Impact of gluten intake on clinical outcomes in patients with chronic inflammatory diseases initiating biologics: Secondary analysis of the prospective multicentre BELIEVE cohort study.
biological treatment
chronic inflammatory disease
gluten
Journal
Scandinavian journal of immunology
ISSN: 1365-3083
Titre abrégé: Scand J Immunol
Pays: England
ID NLM: 0323767
Informations de publication
Date de publication:
02 Oct 2024
02 Oct 2024
Historique:
received:
18
07
2024
accepted:
08
09
2024
medline:
3
10
2024
pubmed:
3
10
2024
entrez:
3
10
2024
Statut:
aheadofprint
Résumé
Chronic inflammatory diseases (CIDs) pose a growing healthcare challenge, with a substantial proportion of patients showing inadequate response to biological treatment. There is renewed interest in dietary changes to optimize treatment regimens, with a growing body of evidence suggesting beneficial effects with adherence to a gluten-free diet. This study compared the likelihood of achieving clinical response to biological treatment after 14-16 weeks in patients with CID with high versus low-to-medium gluten intake. Secondary outcomes of interest included changes in disease activity, health-related quality of life and C-reactive protein. The study was a multicentre prospective cohort of 193 participants with a CID diagnosis (i.e. Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Axial Spondyloarthritis, Psoriatic Arthritis or Psoriasis) who initiated biological treatment between 2017 and 2020. Participants were stratified based on their habitual gluten intake: the upper 33.3% (high gluten intake) and the remaining 66.6% (low-to-medium gluten intake). The proportion of patients achieving clinical response to biological treatment after 14-16 weeks was compared using logistic regression models. The median gluten intake differed significantly between groups (12.5 g/day vs. 5.9 g/day, standardized mean difference = 1.399). In total, 108 (56%) achieved clinical response to treatment, with no difference between 35 (55%) in the high gluten group and 73 (57%) in the medium-to-low gluten group (OR = 0.96 [0.51-1.79], p = 0.897). No differences were found with secondary outcomes. In conclusion, this study found no association between gluten intake and response to biological treatment in patients with CID.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13409Subventions
Organisme : Horizon Foundation
Organisme : Oak Foundation
Organisme : Knud og Edith Eriksens Mindefond
Organisme : Region Syddanmark
Informations de copyright
© 2024 The Author(s). Scandinavian Journal of Immunology published by John Wiley & Sons Ltd on behalf of The Scandinavian Foundation for Immunology.
Références
Cross M, Smith E, Hoy D, et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73(7):1316‐1322. doi:10.1136/annrheumdis-2013-204627
Zhao M, Gönczi L, Lakatos PL, Burisch J. The burden of inflammatory bowel disease in Europe in 2020. J Crohns Colitis. 2021;15(9):1573‐1587. doi:10.1093/ecco-jcc/jjab029
Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377‐385. doi:10.1038/jid.2012.339
Monaco C, Nanchahal J, Taylor P, Feldmann M. Anti‐TNF therapy: past, present and future. Int Immunol. 2015;27(1):55‐62. doi:10.1093/intimm/dxu102
Farrell D, McCarthy G, Savage E. Self‐reported symptom burden in individuals with inflammatory bowel disease. J Crohns Colitis. 2016;10(3):315‐322. doi:10.1093/ecco-jcc/jjv218
Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9(2):136‐139. doi:10.1046/j.1087-0024.2003.09102.x
Salaffi F, Carotti M, Gasparini S, Intorcia M, Grassi W. The health‐related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people. Health Qual Life Outcomes. 2009;7:25. doi:10.1186/1477-7525-7-25
Speca S, Dubuquoy L. Chronic bowel inflammation and inflammatory joint disease: pathophysiology. Joint Bone Spine. 2017;84(4):417‐420. doi:10.1016/j.jbspin.2016.12.016
Li P, Zheng Y, Chen X. Drugs for autoimmune inflammatory diseases: from small molecule compounds to anti‐TNF biologics. Front Pharmacol. 2017;8:460. doi:10.3389/fphar.2017.00460
Ellinghaus D, Jostins L, Spain SL, et al. Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease‐specific patterns at shared loci. Nat Genet. 2016;48(5):510‐518. doi:10.1038/ng.3528
Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58(5):851‐864. doi:10.1016/j.jaad.2008.02.040
Roda G, Jharap B, Neeraj N, Colombel JF. Loss of response to anti‐TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol. 2016;7(1):e135. doi:10.1038/ctg.2015.63
Nielsen OH, Ainsworth MA. Tumor necrosis factor inhibitors for inflammatory bowel disease. N Engl J Med. 2013;369(8):754‐762. doi:10.1056/NEJMct1209614
Fasano A. All disease begins in the (leaky) gut: role of zonulin‐mediated gut permeability in the pathogenesis of some chronic inflammatory diseases. F1000Res. 2020;9:69. doi:10.12688/f1000research.20510.1
Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. Cell Res. 2020;30(6):492‐506. doi:10.1038/s41422-020-0332-7
Sikora M, Stec A, Chrabaszcz M, et al. Gut microbiome in psoriasis: an updated review. Pathogens. 2020;9(6):463. doi:10.3390/pathogens9060463
Wagenaar CA, van de Put M, Bisschops M, et al. The effect of dietary interventions on chronic inflammatory diseases in relation to the microbiome: a systematic review. Nutrients. 2021;13(9):3208. doi:10.3390/nu13093208
Harringer EOS, Durack J, Piceno Y, Andersen V, Lynch SV. Gluten degradation by the gut microbiota of ulcerative colitis patients. Microorganisms. 2022;11(1):12. doi:10.3390/microorganisms11010012
Cabanillas B. Gluten‐related disorders: celiac disease, wheat allergy, and nonceliac gluten sensitivity. Crit Rev Food Sci Nutr. 2020;60(15):2606‐2621. doi:10.1080/10408398.2019.1651689
Lammers KM, Lu R, Brownley J, et al. Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3. Gastroenterology. 2008;135(1):194‐204. e3. doi:10.1053/j.gastro.2008.03.023
Hollon J, Puppa EL, Greenwald B, Goldberg E, Guerrerio A, Fasano A. Effect of gliadin on permeability of intestinal biopsy explants from celiac disease patients and patients with non‐celiac gluten sensitivity. Nutrients. 2015;7(3):1565‐1576. doi:10.3390/nu7031565
Hansen LBS, Roager HM, Søndertoft NB, et al. A low‐gluten diet induces changes in the intestinal microbiome of healthy Danish adults. Nat Commun. 2018;9(1):4630. doi:10.1038/s41467-018-07019-x
Bonder MJ, Tigchelaar EF, Cai X, et al. The influence of a short‐term gluten‐free diet on the human gut microbiome. Genome Med. 2016;8(1):45. doi:10.1186/s13073-016-0295-y
De Palma G, Nadal I, Collado MC, Sanz Y. Effects of a gluten‐free diet on gut microbiota and immune function in healthy adult human subjects. Br J Nutr. 2009;102(8):1154‐1160. doi:10.1017/s0007114509371767
Zaiss MM, Joyce Wu HJ, Mauro D, Schett G, Ciccia F. The gut‐joint axis in rheumatoid arthritis. Nat Rev Rheumatol. 2021;17(4):224‐237. doi:10.1038/s41584-021-00585-3
Chen L, Li J, Zhu W, et al. Skin and gut microbiome in psoriasis: gaining insight into the pathophysiology of it and finding novel therapeutic strategies. Front Microbiol. 2020;11:589726. doi:10.3389/fmicb.2020.589726
Caenepeel C, Sadat Seyed Tabib N, Vieira‐Silva S, Vermeire S. Review article: how the intestinal microbiota may reflect disease activity and influence therapeutic outcome in inflammatory bowel disease. Aliment Pharmacol Ther. 2020;52(9):1453‐1468. doi:10.1111/apt.16096
Di Liberto D, Carlisi D, D'Anneo A, et al. Gluten free diet for the Management of non Celiac Diseases: the two sides of the coin. Healthcare (Basel). 2020;8(4):400. doi:10.3390/healthcare8040400
Bell KA, Pourang A, Mesinkovska NA, Cardis MA. The effect of gluten on skin and hair: a systematic review. Dermatol Online J. 2021;27(4):1.
Badsha H. Role of diet in influencing rheumatoid arthritis disease activity. Open Rheumatol J. 2018;12:19‐28. doi:10.2174/1874312901812010019
Bruzzese V, Scolieri P, Pepe J. Efficacy of gluten‐free diet in patients with rheumatoid arthritis. Reumatismo. 2021;72(4):213‐217. doi:10.4081/reumatismo.2020.1296
Michaëlsson G, Ahs S, Hammarström I, Lundin IP, Hagforsen E. Gluten‐free diet in psoriasis patients with antibodies to gliadin results in decreased expression of tissue transglutaminase and fewer Ki67+ cells in the dermis. Acta Derm Venereol. 2003;83(6):425‐429. doi:10.1080/00015550310015022
Hafström I, Ringertz B, Spångberg A, et al. A vegan diet free of gluten improves the signs and symptoms of rheumatoid arthritis: the effects on arthritis correlate with a reduction in antibodies to food antigens. Rheumatology. 2001;40(10):1175‐1179. doi:10.1093/rheumatology/40.10.1175
Schreiner P, Yilmaz B, Rossel J‐B, et al. Vegetarian or gluten‐free diets in patients with inflammatory bowel disease are associated with lower psychological well‐being and a different gut microbiota, but no beneficial effects on the course of the disease. United European Gastroenterol J. 2019;7(6):767‐781. doi:10.1177/2050640619841249
Missbach B, Schwingshackl L, Billmann A, et al. Gluten‐free food database: the nutritional quality and cost of packaged gluten‐free foods. PeerJ. 2015;3:e1337. doi:10.7717/peerj.1337
Diez‐Sampedro A, Olenick M, Maltseva T, Flowers M. A gluten‐free diet, not an appropriate choice without a medical diagnosis. J Nutr Metab. 2019;2019:2438934. doi:10.1155/2019/2438934
Christensen R, Heitmann BL, Andersen KW, et al. Impact of red and processed meat and fibre intake on treatment outcomes among patients with chronic inflammatory diseases: protocol for a prospective cohort study of prognostic factors and personalised medicine. BMJ Open. 2018;8(2):e018166. doi:10.1136/bmjopen-2017-018166
Overgaard SH, Sørensen SB, Munk HL, et al. Impact of fibre and red/processed meat intake on treatment outcomes among patients with chronic inflammatory diseases initiating biological therapy: a prospective cohort study. Front Nutr. 2022;9:985732. doi:10.3389/fnut.2022.985732
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453‐1457. doi:10.1016/s0140-6736(07)61602-x
Kjeldsen J, Munck LK, Fallingborg J, et al. Behandlingsvejledning med dyre lægemidler til behandling af kroniske inflammatoriske tarmsygdomme [Danish]. Raadet for Anvendelse Af Dyr Sygehusmedicin (RADS). June 1, 2024. Updated December 2017. Accessed June 1, 2024. https://rads.dk/media/4366/beh‐gastro‐31.pdf
Medicinrådets gennemgang af terapiområdet kronisk leddegigt ‐ valg af biologiske og targeterede syntetiske lægemidler [Danish]. Medicinrådet. June 1, 2024. Accessed June 1, 2024. https://medicinraadet‐classic.azureedge.net/media/jdkpo2wm/medicinraadets‐gennemgang‐af‐terapiomraadet‐kronisk‐leddegigt‐vers‐10_adlegacy.pdf
Behandlingsvejledning inkl. lægemiddelrekommandation for anvendelse af biologisk behandling af psoriasisartrit [Danish]. Medicinraadet. June 1, 2024. Updated October 19 2023. Accessed June 1, 2024. https://medicinraadet‐classic.azureedge.net/media/thgdkakk/behandlingsvejl‐inkl‐l%C3%A6gemiddelrekom‐for‐anvendelse‐af‐biologisk‐behandling‐af‐psoriasisartrit‐vers‐1‐8.pdf
Medicinrådets lægemiddelrekommandation vedrørende lægemidler til moderat til svær plaque psoriasis [Danish]. Medicinraadet. June 1, 2024. Accessed June 1, 2024. https://medicinraadet‐classic.azureedge.net/media/ajyhwwpx/medicinradets‐laegemiddelrek‐vedr‐moderat‐til‐svaer‐plaque‐psoriasis‐version‐1‐8.pdf
Eriksen L, Grønbæk M, Helge JW, Tolstrup JS, Curtis T. The Danish health examination survey 2007‐2008 (DANHES 2007‐2008). Scand J Public Health. 2011;39(2):203‐211. doi:10.1177/1403494810393557
Køster‐Rasmussen R, Siersma V, Halldorsson TI, de Fine ON, Henriksen JE, Heitmann BL. Missing portion sizes in FFQ—alternatives to use of standard portions. Public Health Nutr. 2015;18(11):1914‐1921. doi:10.1017/s1368980014002389
Foedevaredatabanken [Dansih]. Foedevareinstituttet, Danmarks Tekniske Universitet. June 1, 2024. Accessed June 1, 2024. https://frida.fooddata.dk/
van Overbeek FM, Uil‐Dieterman IG, Mol IW, Köhler‐Brands L, Heymans HS, Mulder CJ. The daily gluten intake in relatives of patients with coeliac disease compared with that of the general Dutch population. Eur J Gastroenterol Hepatol. 1997;9(11):1097‐1099. doi:10.1097/00042737-199711000-00013
Gellrich C, Schieberle P, Wieser H. Biochemical characterization and quantification of the storage protein (Secalin) types in Rye flour. Cereal Chem. 2003;80(1):102‐109. doi:10.1094/CCHEM.2003.80.1.102
Ellis HJ, Freedman AR, Ciclitira PJ. Detection and estimation of the barley prolamin content of beer and malt to assess their suitability for patients with coeliac disease. Clin Chim Acta. 1990;189(2):123‐130. doi:10.1016/0009-8981(90)90082-4
Khanna R, Bressler B, Levesque BG, et al. Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial. Lancet. 2015;386(10006):1825‐1834. doi:10.1016/s0140-6736(15)00068-9
Vermeire S, O'Byrne S, Keir M, et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet. 2014;384(9940):309‐318. doi:10.1016/s0140-6736(14)60661-9
Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376(7):652‐662. doi:10.1056/NEJMoa1608345
Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab inhibition of interleukin‐17A in patients with psoriatic arthritis. N Engl J Med. 2015;373(14):1329‐1339. doi:10.1056/NEJMoa1412679
Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318‐1328. doi:10.1056/NEJMoa1503824
Sieper J, Rudwaleit M, Baraliakos X, et al. The assessment of SpondyloArthritis international society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009;68(Suppl 2):ii1‐ii44. doi:10.1136/ard.2008.104018
Ware J Jr, Kosinski M, Keller SD. A 12‐item short‐form health survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220‐233. doi:10.1097/00005650-199603000-00003
Hjortswang H, Järnerot G, Curman B, et al. The short health scale: a valid measure of subjective health in ulcerative colitis. Scand J Gastroenterol. 2006;41(10):1196‐1203. doi:10.1080/00365520600610618
Stjernman H, Grännö C, Järnerot G, et al. Short health scale: a valid, reliable, and responsive instrument for subjective health assessment in Crohn's disease. Inflamm Bowel Dis. 2008;14(1):47‐52. doi:10.1002/ibd.20255
Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity‐score matched samples. Stat Med. 2009;28(25):3083‐3107. doi:10.1002/sim.3697
DerSimonian R, Laird N. Meta‐analysis in clinical trials. Control Clin Trials. 1986;7(3):177‐188. doi:10.1016/0197-2456(86)90046-2
Perrin L, Allès B, Buscail C, et al. Gluten‐free diet in French adults without coeliac disease: sociodemographic characteristics, motives and dietary profile. Br J Nutr. 2019;122(2):231‐239. doi:10.1017/s0007114519001053
Pham T, Sokol H, Halioua B, et al. Immune‐mediated inflammatory diseases and nutrition: results from an online survey on patients' practices and perceptions. BMC Nutrition. 2021;7(1):38. doi:10.1186/s40795-021-00446-y
Verdina M, Seibold F, Grandmaison G, et al. Survey of dietary beliefs and habits of inflammatory bowel disease patients. Clin Nutr ESPEN. 2023;57:624‐629. doi:10.1016/j.clnesp.2023.07.090
Crooks B, McLaughlin J, Matsuoka K, Kobayashi T, Yamazaki H, Limdi JK. The dietary practices and beliefs of people living with inactive ulcerative colitis. Eur J Gastroenterol Hepatol. 2021;33(3):372‐379. doi:10.1097/meg.0000000000001911
Munshi Y, Iqbal M, Rafique H, Ahmad Z, Rasheed S. Role of diet in disease activity of arthritis‐a questionnaire based survey. Pak J Nutr. 2008;7:137‐140.
Hawkins P, Earl K, Tektonidis TG, Fallaize R. The role of diet in the management of psoriasis: a scoping review. Nutr Res Rev. 2023;1‐35. doi:10.1017/S0954422423000185
Afifi L, Danesh MJ, Lee KM, et al. Dietary behaviors in psoriasis: patient‐reported outcomes from a U.S. National Survey. Dermatol Ther. 2017;7(2):227‐242. doi:10.1007/s13555-017-0183-4
Covello C, Becherucci G, Scaldaferri F, Laterza L, Gasbarrini A, Mentella MC. Popular diets and nutritional assessment in the management of irritable bowel syndrome in inflammatory bowel disease: an overview of current evidence. Pol Arch Intern Med. 2024;134(2):16659. doi:10.20452/pamw.16659
Lidón AC, Patricia ML, Vinesh D, Marta MS. Evaluation of gluten exclusion for the improvement of rheumatoid arthritis in adults. Nutrients. 2022;14(24):5396. doi:10.3390/nu14245396
Hoppe C, Gobel R, Kristensen M, et al. Intake and sources of gluten in 20‐ to 75‐year‐old Danish adults: a national dietary survey. Eur J Nutr. 2017;56(1):107‐117. doi:10.1007/s00394-015-1062-3
Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. Epidemiology. 2007;18(6):805‐835. doi:10.1097/EDE.0b013e3181577511